JHP Pharmaceuticals to Produce Clinical & Commercial Supply of an Innovative Injectable
JHP Pharmaceuticals recently announced it has entered into an agreement with an undisclosed pharmaceutical company to produce clinical and commercial supply of an innovative injectable used in the cardiovascular setting.
“We are pleased to serve this important customer and recognize that being selected to produce this injectable is based on our expertise with complex formulations coupled with our competence in both clinical supply and commercial supply,” said Stuart Hinchen, President and CEO of JHP. “JHP’s extensive experience working with products through their life cycle, starting with clinical trials through approval, product launch, and global commercialization provides customers with a measure of confidence allowing them to focus on their day-to-day business priorities.”
JHP’s
JHP Pharmaceuticals, headquartered in NJ, provides contract manufacturing of sterile products, including biologics, small molecule, controlled substances, vaccines, ophthalmics, otics, and antibiotics for large and small pharmaceutical and biotech organizations.
JHP’s sterile manufacturing facility, located in
The company has the capability to manufacture small-scale clinical through large-scale commercial products. JHP employs more than 370 staff in the
Total Page Views: 1025
